Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Triple Negative Breast Neoplasms 7Breast Neoplasms 6Lung Neoplasms 5Ovarian Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Endometrial Neoplasms 3Carcinoma, Ovarian Epithelial 3Neoplasms 2Medulloblastoma 2Fallopian Tube Neoplasms 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Urethral Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Thymic epithelial tumor 1Thrombocythemia, Essential 1Stage IIIB or IV Non-Small Cell Lung Cancer 1Squamous NSCLC 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Retinoblastoma 1Recurrence 1Primary Myelofibrosis 1Primary Malignant Neoplasm of Ovary 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

pembrolizumab 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Nonsquamous Non-small Cell Lung Cancer × Carboplatin × Clear all
NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡